Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking method to diabetes management. These innovative therapies operate by mimicking the natural actions of GLP-1, a hormone released by the gut in response to meals. By activating GLP-1 receptors in the pancreas, these compounds increase insulin secretion and reduce glucag

The management of diabetes is with the emergence of exciting new therapies. Among these, Reta, GLP-1 receptor agonists, Retatrutide, and Trizepatide are gaining significant recognition. These medications offer promising approaches for controlling blood sugar levels and may improve the lives of individuals living with diabetes. This novel class of